Dietary saturated fatty acids promote lung myeloid cell inflammasome activation and IL-1β-mediated inflammation in mice and humans
- PMID: 40864681
- PMCID: PMC12866988
- DOI: 10.1126/scitranslmed.adp5653
Dietary saturated fatty acids promote lung myeloid cell inflammasome activation and IL-1β-mediated inflammation in mice and humans
Abstract
Resident tissue macrophages and monocytes (RTMs) integrate local and systemic signals to coordinate immune cell function at homeostasis and in response to inflammatory stimuli. Obesity-associated metabolic dysfunction drives the development of RTM populations that contribute to disease states in multiple tissues. However, the contribution of specific dietary components to innate immune cell activation and function, as opposed to the direct effects of obesity, is largely unknown. Here, we studied the mechanisms by which high-fat (HF) diets shape lung RTM phenotype and function at steady state and influence responses to inflammatory insults. We found that, during HF diet feeding, lung RTMs accumulate saturated long-chain fatty acids, specifically stearic acid (SA), and demonstrate features of NLRP3 inflammasome priming and activation. In vivo, increased dietary SA was sufficient to cause neutrophil-predominant lung inflammation in the steady state and exacerbate a model of innate airway inflammation, whereas increased dietary oleic acid, the monounsaturated counterpart of SA, was sufficient to reduce inflammasome activation in the steady state and attenuate airway inflammation. Depletion of interleukin-1β (IL-1β) or pharmacologic inhibition of the endonuclease inositol requiring enzyme 1α (IRE1α) protected against SA-induced exacerbated lung inflammation. Last, we identified a population of lung monocytes with hallmarks of HF diet-induced RTM activation that were present in samples from obese humans with asthma. Together, these results identify a class of dietary lipids that regulate lung RTM phenotype and function in the steady state and modulate the severity of inflammation in the lung.
Conflict of interest statement
Competing interests:
The authors declare that they have no competing interests.
References
MeSH terms
Substances
Grants and funding
- K24 HL143281/HL/NHLBI NIH HHS/United States
- P30 AI045008/AI/NIAID NIH HHS/United States
- R01 HL162715/HL/NHLBI NIH HHS/United States
- P30 CA016520/CA/NCI NIH HHS/United States
- U01 AI163062/AI/NIAID NIH HHS/United States
- R50 CA211437/CA/NCI NIH HHS/United States
- R01 AI185041/AI/NIAID NIH HHS/United States
- R01 AI164715/AI/NIAID NIH HHS/United States
- K08 DK116668/DK/NIDDK NIH HHS/United States
- T32 DK007314/DK/NIDDK NIH HHS/United States
- R01 HL119503/HL/NHLBI NIH HHS/United States
- P30 DK019525/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
